

## Special Issue

# The Current Status and Trend of Clinical Pharmacology and Clinical Care

### Message from the Guest Editors

Clinical pharmacology encompasses human investigations through randomised controlled trials (RCTs) and evaluating benefit–risk ratios in large populations. In the realm of precision medicine, identifying novel disease phenotypes and endotypes will presumably be helpful in locating new pharmacological targets, patients who respond well to treatments, and patients at risk for adverse drug reactions. On the other hand, developing nucleic acids and phytomolecule-based vaccines and modulating various players of the immune system to address multiple diseases is still a grey area. We invite you to contribute with an original review or research paper, to highlight any of the following: (i) clinical immunology; (ii) research based on traditional formulations already in clinical use for modifying the immune system; (iii) vaccine development and clinical trials in a wide variety of diseases in humans; (iii) phytomolecule- and nucleic acid-based vaccine drug delivery, development and challenges; or (iv) recent advances in novel prophylactic and therapeutic vaccines in clinical trials.

### Guest Editors

Dr. Imran Kazmi

Prof. Dr. Sanmoy Karmakar

Md. Adil Shaharyar

### Deadline for manuscript submissions

closed (1 November 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/150810](https://mdpi.com/si/150810)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).